BATF3, SOCS2, and GPER have emerged as promising gene candidates that may serve as biomarkers or potential therapeutic targets for CAD combined with NASH, linked to the regulation of metabolic, inflammatory, and cardiovascular pathways. The gene discussed is GPER1; the disease is metabolic dysfunction-associated steatohepatitis.